Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional...

[cafead]

via A scathing congressional report has detailed communications described as "inappropriate" and "atypical" between Biogen and the FDA regarding the approval of Alzheimer’s disease drug Aduhelm plus the decision-making behind the pricing and marketing of the now-benched medicine.

article source